Intra-arterial infusion with methotrexate in the rat.
The superiority of intra-arterial infusion with methotrexate (MTX) over its systemic use in the treatment of head and neck tumours is still being questioned. A model in the rat, suitable for intra-arterial administration of MTX could be constructed. In this model 3 schedules have been investigated: (1) 7 days continuous intra-arterial infusion with MTX; (2) the same schedule combined with leucovorin (CF) 6-hourly intraperitoneally (i.p.) after Sullivan et al. (1959); (3) intermittent administration of MTX 2 × 24 h intra-arterial infusion on Day 1 and 4, while on Day 2, 3, 5, 6 and 7 the catheter is kept open by the continuous intra-arterial infusion of saline. For all the three schedules intra-arterial MTX proved to be superior to its systemic use.
D000818:Animals; D002404:Catheterization; D004428:Ear Neoplasms / Q000188:drug therapy; D007269:Injections, Intra-Arterial / Q000379:methods; D007274:Injections, Intraperitoneal; D002955:Leucovorin / Q000008:administration & dosage / Q000627:therapeutic use; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage* / Q000627:therapeutic use; D008954:Models, Biological; D009374:Neoplasms, Experimental / Q000188:drug therapy*; D051381:Rats; D012208:Rhabdomyosarcoma / Q000188:drug therapy
D002955:Leucovorin; D008727:Methotrexate